The estimated Net Worth of Robert Willens is at least $166 Thousand dollars as of 9 May 2013. Mr. Willens owns over 1,000 units of Daxor stock worth over $166,019 and over the last 21 years he sold DXR stock worth over $0. In addition, he makes $0 as Independent Director at Daxor.
Sign up
Mr. Willens DXR stock SEC Form 4 insiders trading
Robert has made over 15 trades of the Daxor stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of DXR stock worth $7,260 on 9 May 2013.
The largest trade he's ever made was buying 2,000 units of Daxor stock on 24 September 2012 worth over $16,600. On average, Robert trades about 838 units every 239 days since 2003. As of 9 May 2013 he still owns at least 18,164 units of Daxor stock.
You can see the complete history of Mr. Willens stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Willens biography
Robert Willens is Independent Director of Daxor Corp., Since 2002. He started an independent consulting firm for investors in early 2008 called Robert Willens LLC. Prior to that he was a Managing Director in the Capital Markets department at Lehman Brothers, Inc., in New York where he specialized in tax and accounting issues and in this capacity advised most areas of the firm regarding the optimal structures for corporate capital transactions. He has been instrumental in developing certain financial “products” with a view towards insuring that these products will provide clients with the desired tax and accounting results. Prior to joining Lehman Brothers in 1987, Mr. Willens was a tax partner in the New York office of what was then known as Peat Marwick. He is a prolific author and has written Taxation of Corporate Capital Transactions, as well as over 200 articles for various professional journals. Each year for the past 10 years, He has been named to Institutional Investor’s “All-American Research” Team. Mr. Willens has been selected, on four different occasions, as one of the 100 “Most Influential Accountants” in the United States by Accounting Today . He serves as Adjunct Professor (Finance Department) at Columbia University’s Graduate School of Business where he teaches the course entitled “Investment Banking Tax Factors.”
How old is Robert Willens?
Robert Willens is 69, he's been the Independent Director of Daxor since 2002. There are 1 older and 6 younger executives at Daxor. The oldest executive at Daxor Corp. is James Lombard, 80, who is the Independent Director.
What's Robert Willens's mailing address?
Robert's mailing address filed with the SEC is 200 EAST 74TH ST APT 18C, , NEW YORK, NY, 10021.
Insiders trading at Daxor
Over the last 21 years, insiders at Daxor have traded over $7,541,627 worth of Daxor stock and bought 473,408 units worth $2,888,339 . The most active insiders traders include Joseph Feldschuh, Bruce Slovin, and Robert J Michel. On average, Daxor executives and independent directors trade stock every 39 days with the average trade being worth of $27,740. The most recent stock trade was executed by Robert J Michel on 27 March 2024, trading 750 units of DXR stock currently worth $6,525.
What does Daxor do?
the bva-100 (blood volume analyzer) is the first instrument of its kind that can precisely measure the amount of blood a patient has in their body. blood volume measurements have been available for almost 60 years, but the test often took 4 to 8 hours to perform and was very difficult to perform accurately. due to these issues, blood volume measurements were very rarely done. physicians had been forced to rely on substitute tests that were only able to measure the thickness of the blood and can be very misleading in many surgical and medical situations. the bva-100 can measure blood volume: accurately, quickly & reliably.
What does Daxor's logo look like?
Complete history of Mr. Willens stock trades at Daxor
Daxor executives and stock owners
Daxor executives and other stock owners filed with the SEC include:
-
Jonathan Adam Feldschuh,
Chief Scientific Officer & Director -
Michael Richard Feldschuh,
Chairman, Pres & CEO -
Diane Meegan,
IR Contact Officer -
Robert Willens,
Independent Director -
James Lombard,
Independent Director -
Joy Goudie,
Independent Director -
Edward Feuer,
Director -
Henry Cremisi,
Director -
Jonathan Feldschuh,
Chief Scientific Officer, Director -
Robert Michel,
Chief Financial Officer -
Michael Feldschuh,
Chairman of the Board, President, Chief Executive Officer -
Robert J. Michel M.B.A., CPA, CPA,
CFO, Chief Compliance Officer & Corp. Sec. -
Guido Manzo,
VP of Sales -
Kathryn A. Kornafel,
VP of Marketing & Commercial Devel. -
Robert J. Michel M.B.A., C.P.A., CPA,
CFO, Chief Compliance Officer & Corp. Sec. -
Caleb Des Rosiers,
Director -
Of Joseph Feldschuh Estate,
10% owner -
Bernhard Saxe,
Director -
Soren Thompson,
VP, Business Development -
Everis Engstrom,
Vice President -
Robert G Moussa,
Director -
Martin S Wolpoff,
Director -
Philip Nordan Hudson,
Director -
Joseph Feldschuh,
President & CEO -
Stephen Valentine,
Director -
Bruce Slovin,
Director -
Gary Joseph Fischman,
President